{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:24:59Z","timestamp":1790893499351,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41585-025-01095-7","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:21:05Z","timestamp":1760368865000},"page":"256-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical translation of polygenic scores for prostate cancer screening"],"prefix":"10.1038","volume":"23","author":[{"given":"Dmitry","family":"Ratner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6113-5564","authenticated-orcid":false,"given":"Jason L.","family":"Vassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319, 1901\u20131913 (2018).","journal-title":"JAMA"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James, N. D. et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683\u20131722 (2024).","journal-title":"Lancet"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei, J. T. et al. Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening. J. Urol. 210, 46\u201353 (2023).","journal-title":"J. Urol."},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","volume":"68","author":"E Castro","year":"2015","unstructured":"Castro, E. et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur. Urol. 68, 186\u2013193 (2015).","journal-title":"Eur. Urol."},{"issue":"Suppl. 6","key":"1095_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.2022.40.6_suppl.155","volume":"40","author":"MS Pagadala","year":"2022","unstructured":"Pagadala, M. S. et al. Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry million veteran program cohort. J. Clin. Oncol. 40 (Suppl. 6), 155 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1095_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/jmg-2024-109845","volume":"61","author":"R Hall","year":"2024","unstructured":"Hall, R., Bancroft, E., Pashayan, N., Kote-Jarai, Z. & Eeles, R. A. Genetics of prostate cancer: a review of latest evidence. J. Med. Genet. 61, 915\u2013926 (2024).","journal-title":"J. Med. Genet."},{"key":"1095_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci, L. A. et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA 315, 68\u201376 (2016).","journal-title":"JAMA"},{"key":"1095_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027130","volume":"6","author":"M Kici\u0144ski","year":"2011","unstructured":"Kici\u0144ski, M., Vangronsveld, J. & Nawrot, T. S. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS ONE 6, e27130 (2011).","journal-title":"PLoS ONE"},{"key":"1095_CR9","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jamaoncol.2024.2185","volume":"10","author":"HH Cheng","year":"2024","unstructured":"Cheng, H. H. et al. BRCA1, BRCA2, and associated cancer risks and management for male patients: a review. JAMA Oncol. 10, 1272\u20131281 (2024).","journal-title":"JAMA Oncol."},{"key":"1095_CR10","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Prostate Cancer Early Detection, Version 2.2025 (NCCN, 2025)."},{"key":"1095_CR11","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2026 (NCCN, 2025)."},{"key":"1095_CR12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","volume":"55","author":"A Wang","year":"2023","unstructured":"Wang, A. et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat. Genet. 55, 2065\u20132074 (2023).","journal-title":"Nat. Genet."},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"UKGPCS Collaborators","year":"2012","unstructured":"UKGPCS Collaborators et al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer 106, 1697\u20131701 (2012).","journal-title":"Br. J. Cancer"},{"key":"1095_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","volume":"65","author":"R Karlsson","year":"2014","unstructured":"Karlsson, R. et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur. Urol. 65, 169\u2013176 (2014).","journal-title":"Eur. Urol."},{"key":"1095_CR15","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/ijc.33024","volume":"147","author":"T Nguyen-Dumont","year":"2020","unstructured":"Nguyen-Dumont, T. et al. Rare germline genetic variants and risk of aggressive prostate cancer. Int. J. Cancer 147, 2142\u20132149 (2020).","journal-title":"Int. J. Cancer"},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/GIM.0b013e3180a6e9ef","volume":"9","author":"JM Gudgeon","year":"2007","unstructured":"Gudgeon, J. M., McClain, M. R., Palomaki, G. E. & Williams, M. S. Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet. Med. 9, 473\u2013478 (2007).","journal-title":"Genet. Med."},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41431-018-0095-5","volume":"26","author":"E Pitini","year":"2018","unstructured":"Pitini, E. et al. How is genetic testing evaluated? A systematic review of the literature. Eur. J. Hum. Genet. 26, 605\u2013615 (2018).","journal-title":"Eur. J. Hum. Genet."},{"key":"1095_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/01.gim.0000227935.26763.c6","volume":"8","author":"SD Grosse","year":"2006","unstructured":"Grosse, S. D. & Khoury, M. J. What is the clinical utility of genetic testing? Genet. Med. 8, 448\u2013450 (2006).","journal-title":"Genet. Med."},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/01.gim.0000179941.44494.73","volume":"7","author":"S Sanderson","year":"2005","unstructured":"Sanderson, S. et al. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet. Med. 7, 495\u2013500 (2005).","journal-title":"Genet. Med."},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-021-03243-6","volume":"591","author":"H Wand","year":"2021","unstructured":"Wand, H. et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature 591, 211\u2013219 (2021).","journal-title":"Nature"},{"key":"1095_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","volume":"53","author":"DV Conti","year":"2021","unstructured":"Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat. Genet. 53, 65\u201375 (2021).","journal-title":"Nat. Genet."},{"key":"1095_CR22","unstructured":"United States Code. Public Health Service Act 42 \u2014 Clinical Laboratory Improvement Amendments of 1988 (USC, 1988)."},{"key":"1095_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1073110520916995","volume":"48","author":"BJ Evans","year":"2020","unstructured":"Evans, B. J. et al. How can law and policy advance quality in genomic analysis and interpretation for clinical care? J. Law Med. Ethics 48, 44\u201368 (2020).","journal-title":"J. Law Med. Ethics"},{"key":"1095_CR24","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.gim.2023.100804","volume":"25","author":"American College of Medical Genetics and Genomics (ACMG)","year":"2023","unstructured":"American College of Medical Genetics and Genomics (ACMG) Laboratory perspectives in the development of polygenic risk scores for disease: a points to consider statement. Genet. Med. 25, 100804 (2023).","journal-title":"Genet. Med."},{"key":"1095_CR25","doi-asserted-by":"publisher","first-page":"100803","DOI":"10.1016\/j.gim.2023.100803","volume":"25","author":"American College of Medical Genetics and Genomics (ACMG)","year":"2023","unstructured":"American College of Medical Genetics and Genomics (ACMG) The clinical application of polygenic risk scores: a points to consider statement. Genet. Med. 25, 100803 (2023).","journal-title":"Genet. Med."},{"key":"1095_CR26","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/gim.2016.40","volume":"18","author":"JE Hunter","year":"2016","unstructured":"Hunter, J. E. et al. A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genet. Med. 18, 1258\u20131268 (2016).","journal-title":"Genet. Med."},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12687-023-00645-z","volume":"14","author":"S Koch","year":"2023","unstructured":"Koch, S., Schmidtke, J., Krawczak, M. & Caliebe, A. Clinical utility of polygenic risk scores: a critical 2023 appraisal. J. Community Genet. 14, 471\u2013487 (2023).","journal-title":"J. Community Genet."},{"key":"1095_CR28","volume":"2","author":"ACF Lewis","year":"2021","unstructured":"Lewis, A. C. F., Green, R. C. & Vassy, J. L. Polygenic risk scores in the clinic: translating risk into action. HGG Adv. 2, 100047 (2021).","journal-title":"HGG Adv."},{"key":"1095_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.63584","volume":"194","author":"L Andreoli","year":"2024","unstructured":"Andreoli, L., Peeters, H., Van Steen, K. & Dierickx, K. Taking the risk: a systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores. Am. J. Med. Genet. A 194, e63584 (2024).","journal-title":"Am. J. Med. Genet. A"},{"key":"1095_CR30","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","volume":"15","author":"J Cuzick","year":"2014","unstructured":"Cuzick, J. et al. Prevention and early detection of prostate cancer. Lancet Oncol. 15, e484\u2013e492 (2014).","journal-title":"Lancet Oncol."},{"key":"1095_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1373\/clinchem.2018.286658","volume":"65","author":"RJ Fantus","year":"2019","unstructured":"Fantus, R. J. & Helfand, B. T. Germline genetics of prostate cancer: time to incorporate genetics into early detection tools. Clin. Chem. 65, 74\u201379 (2019).","journal-title":"Clin. Chem."},{"key":"1095_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41391-022-00497-7","volume":"25","author":"MP Huynh-Le","year":"2022","unstructured":"Huynh-Le, M. P. et al. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 25, 755\u2013761 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1095_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ucl.2021.03.007","volume":"48","author":"L Byrne","year":"2021","unstructured":"Byrne, L. & Toland, A. E. Polygenic risk scores in prostate cancer risk assessment and screening. Urol. Clin. North Am. 48, 387\u2013399 (2021).","journal-title":"Urol. Clin. North Am."},{"key":"1095_CR34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78304","volume":"11","author":"F Chen","year":"2022","unstructured":"Chen, F. et al. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: a meta-analysis within diverse populations. eLife 11, e78304 (2022).","journal-title":"eLife"},{"key":"1095_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei, J. T. et al. Early detection of prostate cancer: AUA\/SUO guideline part II: considerations for a prostate biopsy. J. Urol. 210, 54\u201363 (2023).","journal-title":"J. Urol."},{"key":"1095_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300289","volume":"3","author":"IP Garraway","year":"2024","unstructured":"Garraway, I. P. Prostate cancer foundation screening guidelines for Black men in the United States. NEJM Evid. 3, EVIDoa2300289\u00a0(2024).","journal-title":"NEJM Evid."},{"key":"1095_CR37","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"Grossman, D. C. et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319, 1901\u20131913 (2018).","journal-title":"JAMA"},{"key":"1095_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00266-8","volume":"6","author":"RJ Klein","year":"2022","unstructured":"Klein, R. J. et al. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. npj Precis. Oncol. 6, 25 (2022).","journal-title":"npj Precis. Oncol."},{"key":"1095_CR39","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41591-023-02277-9","volume":"29","author":"L Kachuri","year":"2023","unstructured":"Kachuri, L. et al. Genetically adjusted PSA levels for prostate cancer screening. Nat. Med. 29, 1412\u20131423 (2023).","journal-title":"Nat. Med."},{"key":"1095_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002998","volume":"16","author":"T Callender","year":"2019","unstructured":"Callender, T. et al. Polygenic risk-tailored screening for prostate cancer: a benefit\u2013harm and cost-effectiveness modelling study. PLoS Med. 16, e1002998 (2019).","journal-title":"PLoS Med."},{"key":"1095_CR41","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m, T. et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 22, 1240\u20131249 (2021).","journal-title":"Lancet Oncol."},{"key":"1095_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.7131","volume":"7","author":"L Bj\u00f6rnebo","year":"2024","unstructured":"Bj\u00f6rnebo, L. et al. Biomarker vs MRI-enhanced strategies for prostate cancer screening: the STHLM3-MRI randomized clinical trial. JAMA Netw. Open\u00a07, e247131 (2024).","journal-title":"JAMA Netw. Open"},{"issue":"Suppl. 4","key":"1095_CR43","volume":"209","author":"A Plym","year":"2023","unstructured":"Plym, A. et al. Integration of polygenic risk score with multiparametric MRI in men at risk for clinically significant prostate cancer. J. Urol. 209 (Suppl. 4), e1045 (2023).","journal-title":"J. Urol."},{"key":"1095_CR44","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh, J. K. et al. Assessment of a polygenic risk score in screening for prostate cancer. N. Engl. J. Med. 392, 1406\u20131417 (2025).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 6","key":"1095_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2022.40.6_suppl.231","volume":"40","author":"JK McHugh","year":"2022","unstructured":"McHugh, J. K. et al. The BARCODE1 study in primary care: interim results using a polygenic risk score to target screening. J. Clin. Oncol. 40 (Suppl. 6), 231 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1095_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74172-z","volume":"10","author":"C Sipeky","year":"2020","unstructured":"Sipeky, C. et al. Prostate cancer risk prediction using a polygenic risk score. Sci. Rep. 10, 17075 (2020).","journal-title":"Sci. Rep."},{"key":"1095_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bju.15583","volume":"129","author":"RJ Klein","year":"2022","unstructured":"Klein, R. J. Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis? BJU Int. 129, 271 (2022).","journal-title":"BJU Int."},{"key":"1095_CR48","doi-asserted-by":"publisher","first-page":"j5757","DOI":"10.1136\/bmj.j5757","volume":"360","author":"TM Seibert","year":"2018","unstructured":"Seibert, T. M. et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large-scale cohorts. BMJ 360, j5757 (2018).","journal-title":"BMJ"},{"key":"1095_CR49","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1158\/1055-9965.EPI-19-1527","volume":"29","author":"MP Huynh-Le","year":"2020","unstructured":"Huynh-Le, M. P. et al. A genetic risk score to personalize prostate cancer screening, applied to population data. Cancer Epidemiol. Biomarkers Prev. 29, 1731\u20131738 (2020).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1095_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14248","volume":"8","author":"TJ Hoffmann","year":"2017","unstructured":"Hoffmann, T. J. et al. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. Nat. Commun. 8, 14248 (2017).","journal-title":"Nat. Commun."},{"key":"1095_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04316-y","volume":"21","author":"X Ruan","year":"2023","unstructured":"Ruan, X. et al. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes. J. Transl. Med. 21, 446 (2023).","journal-title":"J. Transl. Med."},{"key":"1095_CR52","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41588-024-02068-z","volume":"57","author":"TJ Hoffmann","year":"2025","unstructured":"Hoffmann, T. J. et al. Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Nat. Genet. 57, 334\u2013344 (2025).","journal-title":"Nat. Genet."},{"key":"1095_CR53","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ajhg.2020.08.025","volume":"107","author":"LG Fritsche","year":"2020","unstructured":"Fritsche, L. G. et al. Cancer PRSweb: an online repository with polygenic risk scores for major cancer traits and their evaluation in two independent biobanks. Am. J. Hum. Genet. 107, 815\u2013836 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR54","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ajhg.2023.05.010","volume":"10","author":"BF Darst","year":"2023","unstructured":"Darst, B. F. et al. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am. J. Hum. Genet. 10, 1200\u20131206\u00a0(2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ng.3446","volume":"48","author":"PRACTICAL Consortium","year":"2016","unstructured":"PRACTICAL Consortium et al. The contribution of rare variation to prostate cancer heritability. Nat. Genet. 48, 30\u201335 (2016).","journal-title":"Nat. Genet."},{"key":"1095_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11112-0","volume":"10","author":"L Duncan","year":"2019","unstructured":"Duncan, L. et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat. Commun. 10, 3328 (2019).","journal-title":"Nat. Commun."},{"key":"1095_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584\u2013591 (2019).","journal-title":"Nat. Genet."},{"key":"1095_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011990","volume":"20","author":"Y Shah","year":"2024","unstructured":"Shah, Y. et al. Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort. PLoS Comput. Biol. 20, e1011990 (2024).","journal-title":"PLoS Comput. Biol."},{"key":"1095_CR59","first-page":"211","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A. & Siegel, R. L. Cancer statistics for African Americans, 2019. CA Cancer J. Clin. 69, 211\u2013233 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"1095_CR60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4111\/icu.20210124","volume":"62","author":"SH Song","year":"2021","unstructured":"Song, S. H. & Byun, S. S. Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: a narrative review. Investig. Clin. Urol. 62, 256\u2013266 (2021).","journal-title":"Investig. Clin. Urol."},{"key":"1095_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44027","volume":"5","author":"K Yamoah","year":"2022","unstructured":"Yamoah, K. et al. Racial and ethnic disparities in prostate cancer outcomes in the veterans affairs health care system. JAMA Netw. Open 5, e2144027 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1095_CR62","unstructured":"National Cancer Institute. Cancer stat facts: prostate cancer. SEER https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html (accessed 4 October 2025)."},{"key":"1095_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00829-7","volume":"13","author":"ACF Lewis","year":"2021","unstructured":"Lewis, A. C. F. & Green, R. C. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Med. 13, 14 (2021).","journal-title":"Genome Med."},{"key":"1095_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euo.2024.04.017","volume":"8","author":"RA Vince","year":"2024","unstructured":"Vince, R. A. et al. Assessing the clinical utility of published prostate cancer polygenic risk scores in a large biobank data set. Eur. Urol. Oncol. 8, 47\u201355 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1095_CR65","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/gepi.20064","volume":"28","author":"H Tang","year":"2005","unstructured":"Tang, H., Peng, J., Wang, P. & Risch, N. J. Estimation of individual admixture: analytical and study design considerations. Genet. Epidemiol. 28, 289\u2013301 (2005).","journal-title":"Genet. Epidemiol."},{"issue":"Suppl. 1","key":"1095_CR66","first-page":"S5","volume":"38","author":"TA Thornton","year":"2014","unstructured":"Thornton, T. A. & Bermejo, J. L. Local and global ancestry inference and applications to genetic association analysis for admixed populations. Genet. Epidemiol. 38 (Suppl. 1), S5\u2013S12\u00a0(2014).","journal-title":"Genet. Epidemiol."},{"key":"1095_CR67","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1101\/gr.094052.109","volume":"19","author":"DH Alexander","year":"2009","unstructured":"Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 19, 1655\u20131664 (2009).","journal-title":"Genome Res."},{"key":"1095_CR68","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ajhg.2013.06.020","volume":"93","author":"BK Maples","year":"2013","unstructured":"Maples, B. K., Gravel, S., Kenny, E. E. & Bustamante, C. D. RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. Am. J. Hum. Genet. 93, 278\u2013288 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR69","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.3390\/ijms22136962","volume":"22","author":"E Suarez-Pajes","year":"2021","unstructured":"Suarez-Pajes, E., D\u00edaz-de Usera, A., Marcelino-Rodr\u00edguez, I., Guillen-Guio, B. & Flores, C. Genetic ancestry inference and its application for the genetic mapping of human diseases. Int. J. Mol. Sci. 22, 6962 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1095_CR70","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajhg.2022.12.010","volume":"110","author":"SR Browning","year":"2023","unstructured":"Browning, S. R., Waples, R. K. & Browning, B. L. Fast, accurate local ancestry inference with FLARE. Am. J. Hum. Genet. 110, 326\u2013335 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR71","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ajhg.2022.03.008","volume":"109","author":"DJ Schaid","year":"2022","unstructured":"Schaid, D. J., Sinnwell, J. P., Batzler, A. & McDonnell, S. K. Polygenic risk for prostate cancer: decreasing relative risk with age but little impact on absolute risk. Am. J. Hum. Genet. 109, 900\u2013908\u00a0(2022).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR72","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-023-02429-x","volume":"29","author":"AP Patel","year":"2023","unstructured":"Patel, A. P. et al. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. Nat. Med. 29, 1793\u20131803 (2023).","journal-title":"Nat. Med."},{"key":"1095_CR73","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41591-022-01767-6","volume":"28","author":"L Hao","year":"2022","unstructured":"Hao, L. et al. Development of a clinical polygenic risk score assay and reporting workflow. Nat. Med. 28, 1006\u20131013 (2022).","journal-title":"Nat. Med."},{"key":"1095_CR74","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jnci\/djac199","volume":"115","author":"MS Pagadala","year":"2023","unstructured":"Pagadala, M. S. et al. Polygenic risk of any, metastatic, and fatal prostate cancer in the million veteran program. J. Natl Cancer Inst. 115, 190\u2013199 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"1095_CR75","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera, A. V. et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67, 2578\u20132589 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1095_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45135-z","volume":"15","author":"Q Sun","year":"2024","unstructured":"Sun, Q. et al. Improving polygenic risk prediction in admixed populations by explicitly modeling ancestral-differential effects via GAUDI. Nat. Commun. 15, 1016 (2024).","journal-title":"Nat. Commun."},{"key":"1095_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15464-w","volume":"11","author":"D Marnetto","year":"2020","unstructured":"Marnetto, D. et al. Ancestry deconvolution and partial polygenic score can improve susceptibility predictions in recently admixed individuals. Nat. Commun. 11, 1628 (2020).","journal-title":"Nat. Commun."},{"key":"1095_CR78","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ajhg.2025.08.006","volume":"112","author":"JA Dias","year":"2025","unstructured":"Dias, J. A. et al. Evaluating multi-ancestry genome-wide association methods: statistical power, population structure, and practical implications. Am. J. Hum. Genet.\u00a0112, 2493\u20132508 (2025).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR79","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1038\/s41467-020-19600-4","volume":"11","author":"L Kachuri","year":"2020","unstructured":"Kachuri, L. et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat. Commun. 11, 6084 (2020).","journal-title":"Nat. Commun."},{"key":"1095_CR80","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.amjcard.2021.02.032","volume":"148","author":"ME Weale","year":"2021","unstructured":"Weale, M. E. et al. Validation of an integrated risk tool, including polygenic risk score, for atherosclerotic cardiovascular disease in multiple ethnicities and ancestries. Am. J. Cardiol. 148, 157\u2013164 (2021).","journal-title":"Am. J. Cardiol."},{"key":"1095_CR81","doi-asserted-by":"publisher","first-page":"100523","DOI":"10.1016\/j.xgen.2024.100523","volume":"4","author":"B Truong","year":"2024","unstructured":"Truong, B. et al. Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases. Cell Genom. 4, 100523 (2024).","journal-title":"Cell Genom."},{"key":"1095_CR82","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/pros.24058","volume":"80","author":"MH Black","year":"2020","unstructured":"Black, M. H. et al. Validation of a prostate cancer polygenic risk score. Prostate 80, 1314\u20131321 (2020).","journal-title":"Prostate"},{"key":"1095_CR83","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.3390\/cancers13225815","volume":"13","author":"A Bakshi","year":"2021","unstructured":"Bakshi, A. et al. A polygenic risk score predicts incident prostate cancer risk in older men but does not select for clinically significant disease. Cancers 13, 5815 (2021).","journal-title":"Cancers"},{"key":"1095_CR84","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamainternmed.2022.6795","volume":"183","author":"KR Schaffer","year":"2023","unstructured":"Schaffer, K. R. et al. A polygenic risk score for prostate cancer risk prediction. JAMA Intern. Med. 183, 386 (2023).","journal-title":"JAMA Intern. Med."},{"key":"1095_CR85","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.juro.2018.10.015","volume":"201","author":"S Li-Sheng Chen","year":"2019","unstructured":"Li-Sheng Chen, S. et al. Risk prediction of prostate cancer with single nucleotide polymorphisms and prostate-specific antigen. J. Urol. 201, 486\u2013495 (2019).","journal-title":"J. Urol."},{"key":"1095_CR86","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/1055-9965.EPI-19-1560","volume":"29","author":"BF Darst","year":"2020","unstructured":"Darst, B. F. et al. The four-kallikrein panel is effective in identifying aggressive prostate cancer in a multiethnic population. Cancer Epidemiol. Biomarkers Prev. 29, 1381\u20131388 (2020).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1095_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa021","volume":"4","author":"G Jia","year":"2020","unstructured":"Jia, G. et al. Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers. JNCI Cancer Spectr. 4, pkaa021 (2020).","journal-title":"JNCI Cancer Spectr."},{"key":"1095_CR88","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41591-020-0800-0","volume":"26","author":"N Mars","year":"2020","unstructured":"Mars, N. et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat. Med. 26, 549\u2013557 (2020).","journal-title":"Nat. Med."},{"key":"1095_CR89","doi-asserted-by":"publisher","first-page":"316.e1","DOI":"10.1016\/j.clgc.2022.09.006","volume":"21","author":"A Siltari","year":"2023","unstructured":"Siltari, A. et al. How well do polygenic risk scores identify men at high risk for prostate cancer? Systematic review and meta-analysis. Clin. Genitourin. Cancer 21, 316.e1\u2013316.e11 (2023).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1095_CR90","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-biodatasci-111721-074830","volume":"5","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Tsuo, K., Kanai, M., Neale, B. M. & Martin, A. R. Challenges and opportunities for developing more generalizable polygenic risk scores. Annu. Rev. Biomed. Data Sci. 5, 293\u2013320 (2022).","journal-title":"Annu. Rev. Biomed. Data Sci."},{"key":"1095_CR91","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/cncr.27941","volume":"119","author":"N Ansbaugh","year":"2013","unstructured":"Ansbaugh, N., Shannon, J., Mori, M., Farris, P. E. & Garzotto, M. Agent orange as a risk factor for high-grade prostate cancer. Cancer 119, 2399\u20132404 (2013).","journal-title":"Cancer"},{"key":"1095_CR92","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2020.2436","volume":"323","author":"JF Figueroa","year":"2020","unstructured":"Figueroa, J. F., Frakt, A. B. & Jha, A. K. Addressing social determinants of health: time for a polysocial risk score. JAMA 323, 1553 (2020).","journal-title":"JAMA"},{"key":"1095_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eururo.2023.01.022","volume":"84","author":"F Chen","year":"2023","unstructured":"Chen, F. et al. Evidence of novel susceptibility variants for prostate cancer and a multi-ancestry polygenic risk score associated with aggressive disease in men of African ancestry. Eur. Urol. 84, 13\u201321 (2023).","journal-title":"Eur. Urol."},{"key":"1095_CR94","doi-asserted-by":"publisher","unstructured":"Dornisch, A. M. et al. Specificity of a polygenic score for aggressive prostate cancer. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.01.23.25321041 (2025).","DOI":"10.1101\/2025.01.23.25321041"},{"key":"1095_CR95","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7326\/0003-4819-158-10-201305210-00633","volume":"158","author":"A Qaseem","year":"2013","unstructured":"Qaseem, A., Barry, M. J., Denberg, T. D., Owens, D. K. & Shekelle, P. Screening for prostate cancer: a guidance statement from the clinical guidelines committee of the American College of Physicians. Ann. Intern. Med. 158, 761\u2013769 (2013).","journal-title":"Ann. Intern. Med."},{"key":"1095_CR96","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/bjc.2015.289","volume":"113","author":"N Pashayan","year":"2015","unstructured":"Pashayan, N. et al. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br. J. Cancer 113, 1086\u20131093 (2015).","journal-title":"Br. J. Cancer"},{"key":"1095_CR97","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eururo.2017.12.028","volume":"74","author":"P Str\u00f6m","year":"2018","unstructured":"Str\u00f6m, P. et al. The Stockholm-3 Model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential. Eur. Urol. 74, 204\u2013210 (2018).","journal-title":"Eur. Urol."},{"key":"1095_CR98","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.2024.42.16_suppl.10500","volume":"42","author":"RA Eeles","year":"2024","unstructured":"Eeles, R. A. et al. Effect of polygenic risk score for clinically significant prostate cancer in a screening program: the BARCODE 1 study results [abstract]. J. Clin. Oncol. 42, 1050 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1095_CR99","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/S0140-6736(24)00912-7","volume":"403","author":"T Burki","year":"2024","unstructured":"Burki, T. Prostate cancer UK launches the TRANSFORM trial. Lancet 403, 1738 (2024).","journal-title":"Lancet"},{"key":"1095_CR100","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.ajhg.2023.10.001","volume":"110","author":"JL Vassy","year":"2023","unstructured":"Vassy, J. L. et al. The GenoVA study: equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care. Am. J. Hum. Genet. 110, 1841\u20131852 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1095_CR101","doi-asserted-by":"publisher","unstructured":"Vassy, J. L. et al. From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS study. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.11.03.24316516 (2024).","DOI":"10.1101\/2024.11.03.24316516"},{"key":"1095_CR102","unstructured":"Color Health. Prostate cancer facts and causes. Color Health https:\/\/www.color.com\/learn\/cancer\/prostate-cancer-facts-and-causes (2025)."},{"key":"1095_CR103","unstructured":"Genomics. Improving health for humanity. Genomics https:\/\/www.genomics.com (2025)."},{"key":"1095_CR104","unstructured":"A3P Biomedical. Stockholm3. A3P https:\/\/www.a3p.com\/about (2024)."},{"key":"1095_CR105","unstructured":"Nucleus Genomics. What\u2019s included. Nucleus https:\/\/mynucleus.com\/whats-included (2025)."},{"key":"1095_CR106","unstructured":"GenePlanet. MyHealth DNA test. GenePlanet https:\/\/geneplanet.com\/eu\/products\/my-health (2025)."},{"key":"1095_CR107","unstructured":"GoPath Global. ProstateNow: delivering clarity for a better tomorrow. GoPath https:\/\/geneticsnow.com\/prostatenow (2025)."},{"key":"1095_CR108","unstructured":"Antegenes. Personalised prostate cancer prevention. Antegenes https:\/\/antegenes.com\/services\/antepc (2024)."},{"key":"1095_CR109","unstructured":"Allelica. Allelica prostate cancer PRS test. Allelica https:\/\/www.allelica.com\/prs-test\/page-3.html (2024)."},{"key":"1095_CR110","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41591-024-02796-z","volume":"30","author":"NJ Lennon","year":"2024","unstructured":"Lennon, N. J. et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat. Med. 30, 480\u2013487 (2024).","journal-title":"Nat. Med."},{"key":"1095_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01117-8","volume":"14","author":"ACF Lewis","year":"2022","unstructured":"Lewis, A. C. F. et al. Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization. Genome Med. 14, 114 (2022).","journal-title":"Genome Med."},{"key":"1095_CR112","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/jpm10040165","volume":"10","author":"AA Lemke","year":"2020","unstructured":"Lemke, A. A. et al. Primary care physician experiences with integrated population-scale genetic testing: a mixed-methods assessment. J. Pers. Med. 10, 165 (2020).","journal-title":"J. Pers. Med."},{"key":"1095_CR113","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/gtmb.2020.0275","volume":"25","author":"AA Lemke","year":"2021","unstructured":"Lemke, A. A. et al. Patient-reported outcomes and experiences with population genetic testing offered through a primary care network. Genet. Test. Mol. Biomarkers 25, 152\u2013160 (2021).","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"1095_CR114","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3122\/jabfm.2021.04.200381","volume":"34","author":"SP David","year":"2021","unstructured":"David, S. P. et al. Implementing primary care\u2013mediated population genetic screening within an integrated health system. J. Am. Board Fam. Med. 34, 861\u2013865 (2021).","journal-title":"J. Am. Board Fam. Med."},{"key":"1095_CR115","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/pme-2021-0102","volume":"18","author":"D Pritchard","year":"2021","unstructured":"Pritchard, D., Hulick, P. J. & Wells, C. J. The integration of personalized medicine into health systems: progress and a path forward. Pers. Med. 18, 527\u2013531 (2021).","journal-title":"Pers. Med."},{"key":"1095_CR116","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2217\/pme.10.13","volume":"7","author":"MA Keller","year":"2010","unstructured":"Keller, M. A. et al. Coriell Personalized Medicine Collaborative: a prospective study of the utility of personalized medicine. Pers. Med. 7, 301\u2013317 (2010).","journal-title":"Pers. Med."},{"key":"1095_CR117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/GIM.0b013e318201164c","volume":"13","author":"CB Stack","year":"2011","unstructured":"Stack, C. B. et al. Genetic risk estimation in the Coriell Personalized Medicine Collaborative. Genet. Med. 13, 131\u2013139 (2011).","journal-title":"Genet. Med."},{"key":"1095_CR118","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10897-011-9476-4","volume":"21","author":"ES Gordon","year":"2012","unstructured":"Gordon, E. S. et al. \u201cIt\u2019s not like Judgment Day\u201d: public understanding of and reactions to personalized genomic risk information. J. Genet. Couns. 21, 423\u2013432 (2012).","journal-title":"J. Genet. Couns."},{"key":"1095_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02699-w","volume":"19","author":"CA Conran","year":"2021","unstructured":"Conran, C. A. et al. Assessing the clinical utility of genetic risk scores for targeted cancer screening. J. Transl. Med. 19, 41 (2021).","journal-title":"J. Transl. Med."},{"key":"1095_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1308738","volume":"14","author":"SP David","year":"2023","unstructured":"David, S. P. et al. Personalized medicine in a community health system: the NorthShore experience. Front. Genet. 14, 1308738 (2023).","journal-title":"Front. Genet."},{"key":"1095_CR121","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1056\/NEJMoa1011893","volume":"364","author":"CS Bloss","year":"2011","unstructured":"Bloss, C. S., Schork, N. J. & Topol, E. J. Effect of direct-to-consumer genome-wide profiling to assess disease risk. N. Engl. J. Med. 364, 524\u2013534 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1095_CR122","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10897-012-9483-0","volume":"21","author":"DJ Kaufman","year":"2012","unstructured":"Kaufman, D. J., Bollinger, J. M., Dvoskin, R. L. & Scott, J. A. Risky business: risk perception and the use of medical services among customers of direct-to-consumer personal genetic testing. J. Genet. Couns. 21, 413\u2013422 (2012).","journal-title":"J. Genet. Couns."},{"key":"1095_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-014-0058-6","volume":"6","author":"SB Haga","year":"2014","unstructured":"Haga, S. B. et al. Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding. Genome Med. 6, 58 (2014).","journal-title":"Genome Med."},{"key":"1095_CR124","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/GIM.0b013e3181eb51c6","volume":"12","author":"CS Bloss","year":"2010","unstructured":"Bloss, C. S. et al. Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet. Med. 12, 556\u2013566 (2010).","journal-title":"Genet. Med."},{"key":"1095_CR125","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/jmedgenet-2012-101207","volume":"50","author":"CS Bloss","year":"2013","unstructured":"Bloss, C. S., Wineinger, N. E., Darst, B. F., Schork, N. J. & Topol, E. J. Impact of direct-to-consumer genomic testing at long-term follow-up. J. Med. Genet. 50, 393\u2013400 (2013).","journal-title":"J. Med. Genet."},{"key":"1095_CR126","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000327296","volume":"15","author":"SE Gollust","year":"2012","unstructured":"Gollust, S. E. et al. Motivations and perceptions of early adopters of personalized genomics: perspectives from research participants. Public Health Genomics\u00a015, 22\u201330 (2012).","journal-title":"Public Health Genomics"},{"key":"1095_CR127","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/cge.12419","volume":"87","author":"DL Boeldt","year":"2015","unstructured":"Boeldt, D. L., Schork, N. J., Topol, E. J. & Bloss, C. S. Influence of individual differences in disease perception on consumer response to direct-to-consumer genomic testing. Clin. Genet. 87, 225\u2013232 (2015).","journal-title":"Clin. Genet."},{"key":"1095_CR128","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12920-021-01056-0","volume":"14","author":"DG Brockman","year":"2021","unstructured":"Brockman, D. G. et al. Design and user-experience testing of a polygenic score report: a qualitative study of prospective users. BMC Med. Genom. 14, 238 (2021).","journal-title":"BMC Med. Genom."},{"key":"1095_CR129","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s43856-023-00269-x","volume":"3","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Deep learning-based polygenic risk analysis for Alzheimer\u2019s disease prediction. Commun. Med. 3, 49 (2023).","journal-title":"Commun. Med."},{"key":"1095_CR130","doi-asserted-by":"publisher","first-page":"75979","DOI":"10.18632\/oncotarget.18275","volume":"8","author":"JJ Oh","year":"2017","unstructured":"Oh, J. J. et al. Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study. Oncotarget 8, 75979\u201375988 (2017).","journal-title":"Oncotarget"},{"key":"1095_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-024-01524-6","volume":"24","author":"AR Hsieh","year":"2024","unstructured":"Hsieh, A. R., Luo, Y. L., Bao, B. Y. & Chou, T. C. Comparative analysis of genetic risk scores for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy. BMC Urol. 24, 136 (2024).","journal-title":"BMC Urol."},{"key":"1095_CR132","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","volume":"53","author":"SA Lambert","year":"2021","unstructured":"Lambert, S. A. et al. The polygenic score catalog as an open database for reproducibility and systematic evaluation. Nat. Genet. 53, 420\u2013425 (2021).","journal-title":"Nat. Genet."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01095-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01095-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01095-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:03:32Z","timestamp":1775649812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01095-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01095-7","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"18 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}